Led by Caroline Huber, Associate Director of Policy and Economics, a surprising new study was recently published in The Journal of Infectious Diseases, estimating the overlooked social, economic and health impacts of the 2013-2016 West Africa Ebola crisis.
In Spotlight on Market Access, Precision senior research economist James Baumgardner provides his perspective on HHS’ proposed changes to Medicare Part D loosening government restrictions on 4 protected drug classes, including those to treat HIV. Baumgardner cautions the rule changes “directly imperils those with HIV who have Medicare as their source of health coverage,” and urges greater adoption of HIV prevention efforts, including the use of new PrEP treatments that can greatly reduce the risk of acquiring HIV.
Harnessing four key strategies, HHS set a goal to virtually eliminate HIV within 10 years—a goal experts believe is achievable. Yet, as reported in Spotlight on Market Access, other HHS policies may be working against that goal. James Baumgardner, senior research economist at Precision Health Economics, shares his insights.
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.
For more information, or to learn how to change your cookies preferences, please click here.